ArticleFuture oncology (London, England)2025

Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancers.

Sara Hurvitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.